<DOC>
	<DOCNO>NCT00954174</DOCNO>
	<brief_summary>This randomized phase III trial study paclitaxel carboplatin see well work compare paclitaxel ifosfamide treat patient newly diagnose persistent recurrent uterine , ovarian , fallopian tube , peritoneal cavity cancer . Drugs use chemotherapy , paclitaxel , carboplatin , ifosfamide , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know whether paclitaxel effective give carboplatin ifosfamide treat patient uterine , ovarian , fallopian tube , peritoneal cavity cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Ifosfamide Treating Patients With Newly Diagnosed Persistent Recurrent Uterine , Ovarian , Fallopian Tube , Peritoneal Cavity Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine treatment combination paclitaxel carboplatin ( TC ) chemotherapy result inferior death rate compare ifosfamide , mesna , paclitaxel chemotherapy . SECONDARY OBJECTIVES : I . To determine treatment combination paclitaxel carboplatin ( TC ) chemotherapy result inferior progression-free survival compare ifosfamide , mesna , paclitaxel chemotherapy . II . To determine acute toxicity , specifically physician-assessed neurotoxicity infection , associate combination paclitaxel carboplatin chemotherapy reduce compare ifosfamide , mesna , paclitaxel chemotherapy . III . To determine treatment combination paclitaxel carboplatin chemotherapy associate superior patient-reported quality life neurotoxicity score compare ifosfamide , mesna , paclitaxel chemotherapy . TERTIARY OBJECTIVES : I . To bank formalin-fixed , paraffin-embedded ( FFPE ) tumor tissue deoxyribonucleic acid ( DNA ) extract whole blood future research . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive paclitaxel intravenously ( IV ) 3 hour carboplatin IV 30-60 minute day 1 . ARM II : Patients receive paclitaxel arm I ifosfamide IV 1 hour day 1-3 . In arm , treatment repeat every 21 day 6-10 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients must newly diagnose stage IIV , persistent recurrent ( include unstaged ) uterine carcinosarcoma ( malignant mixed mullerian tumorMMMT ovarian , fallopian tube peritoneal carcinosarcoma enrollment date prior 10/21/2013 ; pathology confirm site/institutional pathologist prior enrollment ) chemotherapy na√Øve direct carcinosarcoma ; unstaged patient ( patient hysterectomy ovarian surgery ) eligible include `` unstaged '' histologic ( pathology ) documentation disease biopsy curettage uterus ; patient document metastatic disease , assign appropriate stage ( III/IV ) Patients may receive prior adjuvant external beam radiation therapy and/or vaginal brachytherapy ; patient least 4 week completion external beam radiotherapy prior begin protocol chemotherapy ; patient need delay receive vaginal brachytherapy Gynecologic Oncology Group ( GOG ) performance status 0 , 1 , 2 Patients must recover effect recent surgery , radiotherapy , therapy Patients must free active infection require antibiotic Any hormonal therapy direct malignant tumor must discontinue least one week prior begin protocol chemotherapy ; continuation hormone replacement therapy permit Platelet count great equal 100,000/mcL Absolute neutrophil count ( ANC ) great equal 1,500/mcL equivalent Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 grade 1 Creatinine less equal 1.5 time upper limit normal ( ULN ) , CTCAE v3.0 grade 1 Bilirubin less equal 1.5 time ULN ( CTCAE v3.0 grade 1 ) Serum glutamic oxaloacetic transaminase ( SGOT ) less equal 2.5 time ULN ( CTCAE v3.0 grade 1 ) Alkaline phosphatase less equal 2.5 time ULN ( CTCAE v3.0 grade 1 ) Serum albumin equal great 3 g/dL Neuropathy ( sensory motor ) less equal CTCAE v3.0 grade 1 Patients must sign approve informed consent authorization permit release personal health information Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception Patients may measurable disease nonmeasurable disease ; measurable disease define least one lesion accurately measure least one dimension ( long dimension record ) ; lesion must &gt; = 20 mm measure conventional technique , include palpation , plain xray , compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , &gt; = 10 mm measure spiral CT ; measurable disease patient must least one `` target lesion '' use ass progression protocol define Response Evaluation Criteria In Solid Tumors ( RECIST ) ; tumor within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence least 90 day follow completion radiation therapy Patients receive prior cytotoxic chemotherapy management uterine ovarian carcinosarcoma Patients history invasive malignancy concomitant invasive malignancy , exception nonmelanoma skin cancer , evidence malignancy present within last five year ; patient also ineligible previous cancer treatment contraindicate protocol therapy Patients radiotherapy plan chemotherapy prior progression cancer Patients know hypersensitivity E. coliderived drug preparation ( pegfilgrastim filgrastim [ GCSF ] ) Patients know hypersensitivity mesna thiol compound For enrollment prior 10/21/2013 , patient biopsy proven carcinosarcoma uterus , fallopian tube , peritoneum ovary ; enrollment 10/21/2013 , patient biopsy proven carcinosarcoma uterus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>